Healthcare Providers and Services
Company Overview of Health Diagnostic Laboratory, Inc.
Health Diagnostic Laboratory, Inc., a clinical laboratory, provides general and specialty laboratory testing services. The company focuses on disease state management with supporting clinical laboratory testing targeting patients with cardiovascular disease, heart failure, stroke, diabetes mellitus, metabolic syndrome, and nonalcoholic steatohepatitis or fatty liver disease. It offers general and specialty laboratory testing, disease state management and health improvement programs, and specimen handling services, as well as Web based patient portals. The company also provides blood testing services; and support tools for practitioners/physicians to make personalized plans of care for their ...
737 North 5th Street
Richmond, VA 23219-1551
Founded in 2008
Key Executives for Health Diagnostic Laboratory, Inc.
Compensation as of Fiscal Year 2014.
Health Diagnostic Laboratory, Inc. Key Developments
Corgenix Medical Corp. Announces Strategic Partnership with Health Diagnostic Laboratory, Inc. for the Development of a Clinical Laboratory Developed Test
Oct 28 13
Corgenix Medical Corp. has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix' patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk. Under terms of the multi-year agreement, HDL, Inc. has the rights to use Corgenix technology to develop, validate and offer a clinical LDT that may assist clinicians in predicting an increased risk for heart disease in various patient populations. The initial term of the agreement is three years, with annual renewals thereafter based on certain performance requirements.
GeneNews Limited Enters into Joint Venture to Establish US CLIA Lab
Jul 2 13
GeneNews Limited announced that it has formed a joint venture with two private American companies, Health Diagnostic
Laboratory, Inc. and a sales organization with national capabilities, to establish an accredited clinical laboratory called Innovative Diagnostic Laboratory, LLP. IDL will initially focus on the development and broader US commercialization of ColonSentry and is expected to be functional and certified under the Clinical Lab Improvement Amendments Act ("CLIA") in the third quarter. GeneNews has granted IDL an exclusive license for certain technology related to the ColonSentry test for immediate development and commercialization throughout the United States, excluding the States of New York and New Jersey.
Health Diagnostic Laboratory, Inc. Launches New Blood Test for Stratifying Prediabetic Patients
May 30 13
Health Diagnostic Laboratory, Inc. has launched a new blood test for stratifying prediabetic patients based on the Quantose insulin resistance markers discovered by Metabolon. Insulin resistance is a primary risk factor for type 2 diabetes and cardiovascular complications, and the Quantose biomarkers have been incorporated into HDL's newly launched Diabetes Prevention & Management Panel, or DPMP. The Quantose biomarkers are novel metabolites detected in blood that reflect insulin resistance and detect progression to prediabetes and diabetes earlier than traditional glycemic measures such as HbA1c. By considering insulin resistance, metabolites provide clinicians with a useful tool that goes beyond traditional measures to stratify patients based on their risk for developing diabetes. The Quantose markers are particularly useful in identifying prediabetic patients at the greate risk of disease progression where drug or other interventional therapy may be appropriate.
Similar Private Companies By Industry
Recent Private Companies Transactions